Publications by authors named "Michael N Needle"

Claim this Profile
Q
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Michael Szarek, Michael N Needle, Brian I Rini, Sumanta K Pal, David F McDermott

Clin Genitourin Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
Sumanta K Pal, Bernard J Escudier, Michael B Atkins, Thomas E Hutson, Camillo Porta, Michael N Needle

Eur Urol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Brian I Rini, Sumanta K Pal, Bernard J Escudier, Michael B Atkins, Thomas E Hutson, Michael N Needle

Lancet Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposed modification to the Best Pharmaceuticals for Children Act to benefit pediatric oncology.
Michael N Needle

Pediatr Blood Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The virtue of low-flow toilets.
Michael N Needle

J Clin Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
David G Pfister, Yungpo Bernard Su, Dennis H Kraus, Suzanne L Wolden, Eric Lis, Michael N Needle

J Clin Oncol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Christiane D Thienelt, Paul A Bunn, Nasser Hanna, Arthur Rosenberg, Michael N Needle

J Clin Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Michael J Fisher, Beverly J Lange, Michael N Needle, Anna J Janss, Hui-Kuo G Shu

Pediatr Blood Cancer· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Leonard B Saltz, Neal J Meropol, Patrick J Loehrer, Michael N Needle, Justin Kopit

J Clin Oncol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952.
Seema N Sanghavi, Michael N Needle, Mark D Krailo, J Russell Geyer, Joann Ater

Neuro Oncol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Michael N Needle

Semin Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor as a therapeutic target in head and neck cancer.
James A Bonner, Jennifer De Los Santos, Harlan W Waksal, Michael N Needle, Hoa Q Trummel

Semin Radiat Oncol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis